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Utilising nanoemulsions as vehicles for carrying active pharmaceutical ingredients is 
emerging as a promising approach for the latters’ targeted delivery. For drug molecules to be 
clinically effective, their administration by a route, which provides a proper channel for 
them to reach their target, is of prime importance.  Further, they also need to be suitably 
protected in the biological milieu till they are delivered to the required site of action. 
Nanoemulsions with a mean droplet diameter of about 20-200 nm are extremely versatile in 
this regard. Due to their characteristic size and properties, which includes kinetic stability, 
they are very effective in enveloping and/or solubilising the drugs and successfully 
chaperoning them towards suitable targets. They also cause the drugs to be released in 
controlled and sustained modes, thereby reducing drug toxicity and dumping. Additionally, 
depending on the physiochemical properties of the drugs, nanoemulsions can be structurally 
engineered to maximize their solubilisation as per the required route of delivery, which is 
heavily dependent on the drug structure. Effective targeting can be achieved by 
incorporating suitable homing molecules on their surface, which in turn recognize and bind 
to specific receptors on the target molecules. This review focuses on the different routes by 
which drug loaded nanoemulsions can be administered, thus throwing light on the 
versatility of these vehicles for therapeutic and other related applications. 
 
Key words: Nanoemulsions, therapeutics, oral route, parenteral delivery, transdermal 
application, intranasal administration. 
 
 
Nanoemulsions, with a characteristic 
droplet size of 20-200 nm were developed  
around 20 years ago (Solans et al, 2005; Mason 
et al, 2006; Gutierrez et al, 2008; Anton et al, 
2008). They are often referred to as mini (El 
Aasser & Sudol, 2004) submicron (Bivas-
Benita et al, 2004), ultrafine (Nakajima, 1997) 
or fine dispersed emulsions, and appear 
transparent to the naked eye due to the 
inability of  nanoparticles to scatter light 
(McClements, 2002).  They can be used as 
novel formulations in areas of pharmaceutics, 
cosmetic science, food technology, etc 
(Sonneville-Aubert et al, 2004; Acosta, 2009; 
Sosnik et al, 2010). Their non toxic and non 
irritant nature makes them ideal therapeutic 
agents as they do not damage human and 
animal cells (Aboofazeli, 2010). Their long 
term physical stability confers an additional 
advantage. 
 
Nanoemulsion formulations either 
involve oil droplets dispersed in aqueous 
medium (O/W) or the reverse (W/O) 
(Sadurni et al, 2005; Wulff-Perez et al, 2009; 
Shakeel and Ramadan, 2010). They are non 
equilibrium systems and hence their 
preparation involves the input of a large 
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amount of either energy or surfactants and in 
some cases a combination of both. 
Consequently, high energy or low energy 
methods may direct their syntheses (Tadros et 
al, 2004; Anton and Vandamme, 2009).  
 
The high energy approach utilizes 
mechanical devices to create intensely 
disruptive forces which break up the oil and 
water phases to form nanosized oil droplets. 
This can be achieved with microfluidisers, 
high pressure homogenisers and 
ultrasonicators (Graves et al, 2005; Mason et 
al, 2006; Jafari et al, 2007, Gupta et al., 2010). 
Particle size here will depend on the types of 
instruments employed and their operating 
conditions like time and temperature along 
with sample properties and composition 
(Qian and Mc Clement, 2011). This method 
allows for a greater control of particle size 
and a large choice of composition, which in 
turn controls the stability, rheology and color 
of the emulsion.  
 
 
Fig.1. Nano-emulsion (left) with dia 35nm 
and a macro-emulsion (right) with dia 1µm 
 
The low energy synthesis method is 
interesting because it utilizes the stored 
energy of the system to form small droplets. 
This emulsification can be brought about by 
changing the parameters which would affect 
the hydrophilic lipophilic balance of the 
system like temperature, composition, etc 
(Sole et al, 2006; Kelmann et al., 2007; Ee et al., 
2008; Yang et al, 2009; Freon et al, 2010; Sole et 
al, 2010). Further, a careful selection of 
surfactant - co surfactant combination and 
mixing ratio may also be important 
(Izquierdo et al, 2005). 
 
One of the versatile applications of 
nanoemulsions prepared by either of these 
methods is in the area of drug delivery where 
they act as efficient carriers for bioactives, 
facilitating administration by various routes. 
Their parenteral delivery has been adopted 
for supplying nutritional requirements, 
controlled drug release, vaccine delivery and 
for drug targeting to specific sites 
(Tamilvanan, 2004). Intravenous 
administration of nanoemulsions is shown to 
be very advantageous, particularly due to 
their less than 1 µm droplet size (Tamilvanan 
et al, 2005). The advantages and applications 
of oral drug delivery through these vehicles 
are numerous where the droplet size is 
related to their absorption in the 
gastrointestinal tract (Nicoloas et al, 2003). 
Nanoemulsions have also been studied for 
their use in ocular delivery where 
pharmacological drugs are more sustained 
compared to their respective solutions 
(Tamilvanan, 2004; Rabinovich-Guilatt et al, 
2004). Pulmonary route is another way of 
administering nanoemulsified drugs (Bivas-
Benita et al, 2004). Transdermal delivery 
system is a successful channel wherein drug 
loaded nanoparticles are delivered through 
the skin (Fang et al, 2004; Huailiang et al, 
2001).  
 
This review elaborates on the possible 
routes by which bioactives and active 
pharmaceutical ingredients can be delivered 
using nanoemulsions as vehicles. They can 
subsequently be directed to specific tissue 
and cell targets by the process of passive and 
/or active targeting to prevent and regress 
various pathological conditions (Koo et al, 
2005). 
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ORAL ADMINISTRATION OF DRUG 
LOADED NANOEMULSIONS 
The most convenient, easiest and cost 
effective way for non invasive drug 
administration is by the oral route which 
dominates the drug delivery market (Pinto, 
2010). It is also regarded as the optimal means 
for achieving therapeutic targets due to 
increased patient compliance and efforts are 
on to use this route for personalized medicine 
(Wening and Breitkreutz, 2011) However, this 
route of delivery has its limitations with 
respect to geriatric, pediatric and possibly 
trauma / epileptic patients where patient 
cooperation is a constraint. Alternatively, 
physiochemical properties of certain drugs 
may not be conducive to pathway of 
administration. Oral delivery of drugs with 
poor aqueous solubility poses some serious 
problems with respect to drug stability in the 
gastrointestinal tract. Peptide drugs are 
known to undergo hydrolysis and enzymatic 
degradation which inturn limits their 
intestinal absorption. Their limited ability to 
permeate the membrane and hygroscopic 
nature may present additional drawbacks. 
Many approaches have been put forth to 
increase their bioavailability, which include 
micronization, solid dispersion, complexation 
with cyclodextrins  and use of particulate 
delivery systems which are soluble or 
dispersable in aqueous environment (Francis 
et al, 2004; Brusewitz,  et al., 2007; Sachan et al, 
2010).  These strategies aim to protect the 
drugs from degradation in the 
gastrointestinal tract, prolong the drug transit 
time, and target them to specific sites to assist 
specific absorption pathways.  
 
Niwa et al (2011) have developed wet 
milling techniques to prepare oral nano 
suspensions for poorly soluble drugs. The 
milling techniques, based on stirring, 
oscillating and turbulent motions break drugs 
into miniature particles for incorporation into 
nano suspensions for subsequent delivery. 
The smaller particles may be able to penetrate 
the GIT membrane to a better extent which 
could not have been feasible by the 
conventional delivery. In this case however, 
extensive optimization of formulations and 
process variables needs to be carried out 
especially from the industrial perspective 
(Singare et al, 2010). The targeting of 
nanoparticulate drug carriers, which have 
been used for  HIV/AIDS therapy, to viral 
reservoir sites with subsequent lowering of 
the viral loads below the detection limit, has 
been reviewed (Vyas et al, 2006). O/W 
nanoemulsions made with polyunsaturated 
fatty acids and loaded with Saquinivir may 
also be promising for HIV-AIDS therapy by 
enhancing oral bioavailability and brain 
disposition (Vyas et al, 2008).  
 
Paclitaxel (PTX), a diterpenoid 
pseudoalkaloid, is an antineoplastic drug 
with proven activity against a number of 
tumors. O/W nanoemulsions prepared with 
this drug, containing pine nut oil as the 
lipophilic phase and egg lecithin as emulsifier 
and prepared by sonication showed 
improved bioavailability as detected in the 
systemic circulation when compared to 
administration of control aqueous solution. 
The absorbed drug was found to be 
distributed in the liver, kidneys, and lungs 
showing promising targeting effects (Tiwari 
and Amiji, 2006). Further, the association 
between PTX-2 hydroxypropyl beta 
cyclodextrin and polyanhydride nano 
particles induces a positive effect over the 
intestinal permeability of the drug (Agueros 
et al, 2009). The in vitro transport of beta 
lactamase, by self nano emulsifying drug 
delivery system (SNEDDS), was studied by 
Rao et al (2008). All the SNEDDS showed 
higher transport rate than free solutions, with 
transport rate depending on their 
composition. Hence it was reported to be a 
very effective non invasive delivery system 
for proteins. The absorption of ramiprilat 
from ramipril with nanoemulsions was 
reported to be 2.94 times compared to 
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conventional capsules and 5.4 times 
compared to drug suspensions. Hence its use 
for geriatric and pediatric patients was 
recommended (Shafiq et al, 2007). 
 
 In the gastrointestinal tract, the oils 
are effectively absorbed through various lipid 
absorption mechanisms. Thus, one of the best 
ways to increase the absorption of drugs, 
specially the protein drugs, is to load them 
inside the oils, such that there would be a 
significant increase in the level of absorption 
of drugs along with the oils. An innovative 
strategy is to use oils as components of 
nanoemulsions to load the drugs, ultimately 
leading to increased absorption of drugs in 
gastro intestinal tract. Use of nanoemulsions 
in the oral drug delivery systems is known to 
bring about promising results in increasing 
the effectiveness of the drug to the target site. 
This system of delivery can bring about the 
enhancement of the drug bioavailability, 
enhanced permeability, cell and tissue 
targeting, imaging, and therapeutic functions 
(Ganta et al, 2010).  
 
 
NANOEMULSION BASED PARENTERAL 
DRUG DELIVERY SYSTEMS 
This is one of the most common and effective 
routes for the drug administration usually 
adopted for actives with low bioavailability 
and narrow therapeutic index. The stability of 
nanoemulsions used here mainly depends 
upon the composition, preparation 
techniques and storage conditions. Their 
capacity to dissolve large quantities of 
hydrophobics, along with their mutual 
compatibility and ability to protect the drugs 
from hydrolysis and enzymatic degradation 
makes them ideal vehicles for the purpose of 
parenteral transport.  
 
Further, the frequency and dosage of 
injections can be reduced throughout the 
drug therapy period as these emulsions 
guarantee the release of drugs in a sustained 
and controlled mode over long periods of 
time. Additionally, the lack of flocculation, 
sedimentation and creaming, combined with 
a large surface area and free energy, offer 
obvious advantages over emulsions of larger 
particle size, for this route of administration. 
Their very large interfacial area positively 
influences the drug transport and their 
delivery, along with targeting them to 
specific sites. Major clinical and preclinical 
trials have hence been carried out with 
parenteral nanoemulsion based carriers. The 
advances in these novel drug delivery 
systems have been reviewed by Patel and 
Patel (2010).  
 
Parenteral administration of drugs 
had a major breakthrough after the successful 
use of fat emulsions in 1960s. Since then, 
there had been a development in nano based 
products which indicated the interest of 
pharmaceutical industry in such vehicles for 
delivery by this route. The use of lipid 
nanoparticles for the parenteral delivery of 
actives has been reviewed (Joshi and Muller, 
2009). The utility of these, as adjuvants, 
confers an additional advantage in spite of 
some toxicity being caused by them. A 
similar review discusses the parameters 
which influence encapsulation of drugs along 
with their release and biodistribution with in 
vivo/in vitro toxicity and efficacy case studies 
(Constantinides et al., 2008).  
 
Tocol nanoemulsions offer an 
appealing alternative for drug delivery by 
this route. The utility of tocol based 
emulsions are numerous (Constantinides et 
al., 2004). Nanoemulsions loaded with 
thalidomide have been synthesized where a 
dose as low as 25mg leads to plasma 
concentrations which can be therapeutic 
(Araujo et al., 2011). However, a significant 
decrease in the drug content of the 
nanoemulsion was observed at 0.01% drug 
formulation after two months storage which 
could be overcome by the addition of 
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polysorbate 80. Nanostructured lipid carriers 
(NLC) have also been used for carrying 
Silybin, a poorly water soluble 
antihepatopathy agent, by the intravenous 
route in rabbits and mice. The results showed 
higher AUC (Area under tissue concentration 
curve) values with NLC linked silybin 
circulating in the blood for a longer period 
than silybin solution. The drug uptake was 
also found to be higher in the tissues, 
suggesting the potential role for NLC in 
sustained drug release and efficient uptake 
by cells (Jia et al, 2010). 
 
Chlorambucil, a lipophilic anticancer 
agent has been used against breast and 
ovarian cancer. Its pharmacokinetics and 
anticancer activity has been studied by 
loading it in parenteral emulsions prepared 
by high energy ultrasonication method. 
Treatment of colon adenocarcinoma in the 
mouse with this nanoemulsion leads to 
higher tumor suppression rate compared to 
plain drug solution treatment concluding that 
the drug loaded emulsion could be an 
effective carrier for its delivery in cancer 
treatment (Ganta et al, 2008). Carbamazipine, 
a widely used anticonvulsant drug had no 
parenteral treatment available for patients 
due to its poor water solubility. Kelmann et al 
(2007) have developed a nanoemulsion for its 
intravenous delivery which showed favorable 
in vitro release kinetics.  
 
The nano interventions for 
neurodegenerative disorders have been 
reviewed by Fernandes et al (2010). The use of 
nanoparticles to deliver drugs to the brain 
infiltrating the blood brain barrier may open 
up new strategies to overcome the challenges 
posed by the anatomical barriers of the brain. 
Further, the ability of these nanoparticles to 
cross the barrier without altering the original 
characteristics of the therapeutic drug 
molecule offer additional advantages. 
 
EFFICACY OF NANOEMULSIONS IN 
TRANSDERMAL DELIVERY OF DRUGS 
Drug delivery through the skin to the 
systemic circulation is convenient for a 
number of clinical conditions due to which 
there has been a considerable interest in this 
area (Muller - Goymann, 2004; Gaur et al., 
2009). It offers the advantage of steady state 
controlled drug delivery over  extended 
periods of time, with self administration also 
being possible, which may not be the case 
with parenteral route. The drug input can be 
eliminated at any time by the patient just by 
removing the transdermal patch. An extra 
advantage is the total absence of 
gastrointestinal side effects like irritation and 
bowel ulcers which are invariably associated 
with oral delivery. Transdermal drug 
products have been developed for a number 
of diseases and disorders including 
cardiovascular conditions, Parkinsons’ and 
Alzheimer diseases, anxiety, depression, etc.  
 
However, the fundamental 
disadvantage which limits the use of this 
mode of administration is the barrier 
imposed by the skin for effective penetration 
of the bioactives. The three routes by which 
drugs can primarily penetrate the skin are 
through the hair follicles, sweat ducts or 
directly across stratum corneum which 
restricts their absorption to a large extent and 
limits their bioavailability. For improved 
drug pharmacokinetics and targeting, the 
primary skin barriers need to be overcome. 
Also the locally applied drug redistribution 
through cutaneous blood and lymph vessel 
system needs to be controlled.  
 
Nanotechnology with the use of nano 
sized particles has largely succeeded in 
overcoming this barrier and have proved to 
be much better than microemulsions (Kotyla 
et al, 2008; Cevc and Vierl, 2010). Nano sized 
emulsions are able to easily penetrate the 
pores of the skin and reach the systemic 
circulation thus getting channelized for 
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effective delivery. There are different ways by 
which the skin penetration of drugs can be 
enhanced. This includes optimization of drug 
and vehicle properties, for e.g., maximum 
penetration is observed when the drug is at 
its maximum thermodynamic activity like in 
the case of supersaturated solution (Benson, 
2005; Yilmaz and Borchert, 2006; Klang et al, 
2010). 
 
Caffeine has been used for treatment 
of different types of cancer by oral delivery. 
Water in oil nanoemulsion formulations of 
caffeine has been developed for transdermal 
drug delivery. Comparison of in vitro skin 
permeation profile between these and 
aqueous caffeine solutions showed significant 
increase in permeability parameters for the 
nanoemulsion loaded drugs (Shakeel and 
Ramadan, 2010).  
 
The development of magnetic 
nanoemulsions is an innovative approach for 
cancer therapy. These can deliver 
photosensitizers like Foscan to deep tissue 
layers across the skin thereby inducing 
hyperthermia for subsequent free radical 
generation. This methodology can be used for 
the treatment of cancer in the form of 
photodynamic therapy (Primo et al., 2007). 
Shakeel et al. (2008) have reported the 
comparative pharmacokinetic profile of 
aceclofenac obtained from oral delivery and 
transdermal application inferring that the 
absorption of this drug in the latter case 
resulted in 2.95 fold increase in 
bioavailability. 
 
Use of nanoemulsions in transdermal 
drug delivery represents an important area of 
research in drug delivery, which enhances the 
therapeutic efficacy and also the 
bioavailability of the drugs without any 
adverse effects. It is also regarded as a 
promising technique with many advantages 
including, high storage stability, low 
preparation cost, thermodynamic stability, 
absence of organic solvents, and good 
production feasibility. They have also made 
the plasma concentration profiles and 
bioavailability of drugs reproducible. These 
systems are being used currently to provide 
dermal and surface effects, for deeper skin 
penetration, etc.  
 
 NANOEMULSIONS FOR INTRANASAL 
ROUTE OF DRUG DELIVERY 
Intranasal drug delivery system has now 
been recognized as a reliable route for the 
administration of drugs next to parenteral 
and oral routes. Nasal mucosa has emerged 
as a therapeutically viable channel for the 
administration of systemic drugs and also 
appears to be a favorable way to overcome 
the obstacles for the direct entry of drugs to 
the target site (Pires et al., 2009). This system 
has been accepted in the Ayurvedic system of 
Indian medicine and in the recent times, this 
is mostly preferred over the oral 
administration due to their better systemic 
bioavailability, as the gastrointestinal 
metabolism of the drug is avoided 
(Rahisuddin et al., 2011). This route is also 
painless, non invasive and tolerated 
favorably. 
 
There are several problems associated 
with targeting drugs to brain, especially the 
hydrophilic ones and those of high molecular 
weight. This is because of the impervious 
nature of the endothelium which divides the 
systemic circulation and barrier between the 
blood and brain (Pardridge, 1999). The 
olfactory region of the nasal mucosa provides 
a direct connection between the nose and  
brain, and by the use of nanoemulsions 
loaded with drugs, conditions such as 
Alzheimer’s disease, migraine, depression, 
schizophrenia, Parkinson’s diseases, 
meningitis, etc. can be treated (Kumar et al., 
2008; Mistry et al., 2009). 
 
 It is particularly more useful 
compared to oral and parenteral routes 
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among pediatric patients as the former routes 
may increase the anxiety among them 
(Goldman, 2006). Mistry et al. (2009) have 
reviewed the use of nanoparticles for the 
direct delivery of drugs from nose to brain. 
They also emphasize for the need for 
evaluating the toxicity of the nanoparticle 
delivery system through the nasal route. 
Preparation of nanoemulsions containing 
risperidone for its delivery to the brain via 
nose has been reported (Kumar et al., 2008).  It 
is inferred that this emulsion is more effective 
through the nasal rather than intravenous 
route. These types of emulsions can also be 
used as a non toxic mucosal adjuvant for 
influenza vaccine virus (Myc et al., 2003). 
 
Another application of intranasal 
drug delivery system in therapeutics is their 
use in development of vaccines. Immunity is 
achieved by the administration of mucosal 
antigen. Currently, the first intranasal vaccine 
has been marketed (Csaba, 2009). The nasal 
cavity is one of the most efficient sites 
because of its reduced enzymatic activity, 
high availability of immuno active sites and 
its moderately permeable epithelium 
(Ugwoke, 2005). Among the possible delivery 
systems, the use of nano based carriers hold a 
great promise to protect the biomolecules, 
promote nanocarrier interaction with 
mucosae and to direct antigen to the 
lymphoid tissues.  Therefore the use of 
nanoemulsions in intranasal drug delivery 
system is set to bring about significant results 
in targeting drugs to the brain in treatment of 
diseases related to the central nervous system 
(Clark et al, 2001). 
 
Limitations in intra nasal delivery 
systems include interaction of drug with 
nasal mucosa thereby influencing the nasal 
drug absorption and also its therapeutic 
efficacy (Illum, 2002). Moreover, only 
restricted amounts of drug formulations can 
be administrated due to the low volume of 
the nasal cavity (Costantino, 2007). 
OTHER ROUTES OF DRUG DELIVERY 
WITH NANOEMULSIONS 
Alternative routes used for nano emulsion 
based drug delivery is through the ocular 
channel. In the last decade, oil-in-water 
emulsions have been exploited for the 
development and improvement of ocular 
bioavailability (Tamilvanan and Benita, 2004). 
Ocular drug delivery is one of the most 
challenging routes due to the critical and 
pharmacokinetically specific environment 
that exist in the eyes (Koevary, 2003; Behar-
Cohen, 2004). Kumaran et al. (2010) have 
reviewed the conventional and advanced 
ocular delivery formulations with respect to 
their applicability, acceptance, characteristics 
and utility. Hydrocortisone nanosuspensions 
showed sustained effects with significant 
improvement in ocular bioavailability. This 
was in comparison to the drug solution, and 
provides an opportunity to decrease the 
administration frequency and also improve 
patient compliance for drug delivery by this 
route (Ali et al.,2011). 
 
The cytosolic drug delivery system 
using nanoemulsions is also promising, 
which is an efficient route for the 
administering drugs that undergo a large cell 
efflux through the transporters like multi 
drug resistant proteins (Panyam and 
Labhasetwar, 2004). Research associated with 
the use of nanoparticles for cytosolic drug 
delivery is under progress. These 
nanoparticles are being developed in such a 
way that along with targeting the drug to the 
action site, their concentrations can also be 
maintained at required levels for a longer 
time period (Vasir and Labhasetwar, 2007).  
 
CONCLUSION 
Nanoemulsions have been intensively 
exploited for their significant applications in 
therapeutics and pharmaceutics. Their 
versatile properties include enhanced drug 
loading capabilities along with offering the 
drugs sufficient protection in the biological 
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environment. Some multifunctional 
nanocarriers also direct the drugs to specific 
targets with attached homing molecules 
guiding them to the required site of action. 
This has lead to the development of smart 
nanoemulsions with tremendous potential for 
the focused treatment of various pathological 
conditions like cancer and atherosclerosis. 
The major routes for the administration of 
drugs using these vehicles, viz., oral, 
parenteral, transdermal and intranasal 
channels, have been reviewed here. 
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